Company profile: Akari Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics focused on development and commercialization of innovative treatments, including nomacopan, a bispecific recombinant inhibitor targeting complement C5 and LTB4 for autoimmune and inflammatory diseases; a Phase 3 HSCT-TMA program for pediatric and adult transplant-related thrombotic microangiopathy; and PAS-nomacopan, a long-acting candidate for geographic atrophy.
Products and services
- HSCT-TMA: A Phase 3 clinical trial program investigating nomacopan for treating pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy
- Nomacopan: A bispecific recombinant inhibitor targeting complement C5 and leukotriene B4 (LTB4) activity, being developed for various autoimmune and inflammatory diseases
- PAS-nomacopan: A long-acting version of nomacopan in pre-clinical development for geographic atrophy, aiming to reduce injection frequency and risk of choroidal neovascularization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akari Therapeutics
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Vaccinex
HQ: United States
Website
- Description: Provider of therapeutic antibody discovery and development focused on neurodegeneration, oncology and autoimmune diseases. Offers Pepinemab, a monoclonal antibody targeting SEMA4D in clinical trials for cancers, Huntington's and Alzheimer's; ActivMAb, a platform for antibody discovery against complex antigens; and VX5/5261, a CXCL13-targeting antibody in preclinical development for rheumatoid arthritis and multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinex company profile →
ImmuneXcite
HQ: United States
Website
- Description: Provider of a platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for disease targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuneXcite company profile →
Vitaeris
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical development by a Canadian company focused on the anti-interleukin-6 monoclonal antibody Clazakizumab, with global exclusive rights licensed from Alder Biopharmaceuticals, pursuing applications in chronic inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitaeris company profile →
Tizona Therapeutics
HQ: United States
Website
- Description: Provider of next-generation immunotherapies, including TTX-080, an investigational antibody targeting HLA-G evaluated as monotherapy and in combination in patients with advanced cancers; TTX-030, a monoclonal antibody inhibiting CD39 studied with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer; and TZ-040, a pre-clinical program anticipated to enter IND-enabling studies targeting novel immuno-modulatory molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tizona Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akari Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akari Therapeutics
2.2 - Growth funds investing in similar companies to Akari Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akari Therapeutics
4.2 - Public trading comparable groups for Akari Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →